IRIS
SALADINI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.352
EU - Europa 5.491
AS - Asia 2.681
SA - Sud America 520
AF - Africa 169
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.220
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.241
RU - Federazione Russa 1.294
GB - Regno Unito 1.189
SG - Singapore 838
IT - Italia 770
CN - Cina 761
IE - Irlanda 691
BR - Brasile 433
SE - Svezia 386
VN - Vietnam 330
DE - Germania 284
FR - Francia 260
HK - Hong Kong 248
UA - Ucraina 219
IN - India 122
FI - Finlandia 120
KR - Corea 99
ES - Italia 95
ZA - Sudafrica 94
CA - Canada 57
BD - Bangladesh 44
NL - Olanda 40
BE - Belgio 37
TR - Turchia 34
AR - Argentina 32
JP - Giappone 32
MX - Messico 31
PL - Polonia 27
IQ - Iraq 24
NG - Nigeria 24
PK - Pakistan 19
UZ - Uzbekistan 18
ID - Indonesia 14
EC - Ecuador 13
LT - Lituania 13
AT - Austria 12
CZ - Repubblica Ceca 12
IR - Iran 12
KE - Kenya 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
CO - Colombia 10
KZ - Kazakistan 10
EG - Egitto 9
GR - Grecia 9
MA - Marocco 8
PY - Paraguay 8
SA - Arabia Saudita 8
JM - Giamaica 7
BO - Bolivia 6
EE - Estonia 6
ET - Etiopia 6
SK - Slovacchia (Repubblica Slovacca) 6
MY - Malesia 5
NP - Nepal 5
PT - Portogallo 5
AL - Albania 4
BH - Bahrain 4
CL - Cile 4
DO - Repubblica Dominicana 4
HN - Honduras 4
IL - Israele 4
JO - Giordania 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
TN - Tunisia 4
AU - Australia 3
DZ - Algeria 3
LB - Libano 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
AO - Angola 2
AZ - Azerbaigian 2
BW - Botswana 2
CI - Costa d'Avorio 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
PE - Perù 2
SN - Senegal 2
TM - Turkmenistan 2
AM - Armenia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 15.212
Salva come PNG Salva come JPEG
Città #
Southend 1.017
Dallas 857
Dublin 687
Fairfield 627
Singapore 459
Ashburn 441
Chandler 391
Moscow 357
Santa Clara 313
San Jose 293
Woodbridge 270
Beijing 242
Hong Kong 239
Siena 236
Seattle 228
Cambridge 224
Ann Arbor 213
Houston 210
Wilmington 201
Jacksonville 179
Munich 117
New York 113
Princeton 111
Ho Chi Minh City 102
Hefei 99
Los Angeles 99
Seoul 96
Johannesburg 89
Hanoi 68
Lauterbourg 68
Málaga 66
Rome 64
Council Bluffs 63
Milan 63
The Dalles 63
Helsinki 59
Nanjing 48
San Mateo 44
São Paulo 44
Boardman 42
Bengaluru 36
Buffalo 36
Shanghai 36
Dong Ket 33
Brussels 31
Orem 30
San Diego 30
London 28
Dearborn 27
Montreal 27
Tokyo 26
Hangzhou 25
Abuja 23
Columbus 23
Portsmouth 22
Chennai 21
Frankfurt am Main 21
Redondo Beach 21
Turku 20
Warsaw 20
Menlo Park 19
Nanchang 19
Atlanta 18
Manchester 17
Phoenix 17
Tashkent 17
Denver 16
North Bergen 16
Nuremberg 16
Mexico City 15
Toronto 15
Redwood City 14
Stockholm 14
Amsterdam 13
Fremont 13
Shenyang 13
Düsseldorf 12
Izmir 12
Mumbai 12
Naples 12
San Francisco 12
Belo Horizonte 11
Brooklyn 11
Chicago 11
Dhaka 11
Hebei 11
Lappeenranta 11
Baghdad 10
Boston 10
Brasília 10
Da Nang 10
Lancaster 10
Norwalk 10
Tianjin 10
Changsha 9
Florence 9
Rio de Janeiro 9
Astana 8
Guangzhou 8
Hillsboro 8
Totale 10.237
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 326
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 317
A novel methodology for large-scale phylogeny partition 299
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 299
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 298
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 296
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 296
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 292
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 285
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 283
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 272
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 261
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 257
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 255
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 254
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 253
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 250
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 250
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 243
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 242
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 240
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 239
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 239
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 237
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 236
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 234
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 234
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 232
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 229
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 229
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 229
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 228
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 219
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors 212
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein 211
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 209
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 208
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 205
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 201
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 200
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 198
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients 188
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 183
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo Basin 182
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 181
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 178
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 178
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 175
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 173
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 161
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects 157
Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 155
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 155
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 145
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 144
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 141
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 140
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 140
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 140
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 138
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 138
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 135
null 129
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes 127
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 123
null 121
null 114
null 114
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 114
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry 110
Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of HIV-1 unique recombinant forms 110
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 100
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 93
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 93
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance 92
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 85
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 80
HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users 76
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy 67
HIV-1 nucleocapsid inhibitors 67
Identification of a possible ancestor of the subtype A1 HIV type 1 variant circulating in the former Soviet Union (Aids Research and Human Retroviruses) 44
Molecular Epidemiology of HIV-1 in Eastern Europe and Russia 42
null 32
Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia 14
Totale 15.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.690
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.690
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021104 0 0 0 0 0 0 0 0 0 0 0 104
2021/20221.137 68 130 82 117 78 50 63 54 71 109 114 201
2022/20231.326 72 186 143 155 129 236 69 95 96 79 43 23
2023/20241.061 33 24 75 65 15 302 376 31 4 18 25 93
2024/20252.279 50 94 294 115 282 171 78 142 206 114 236 497
2025/20265.563 402 746 757 776 1.259 198 554 187 199 292 127 66
Totale 15.471